Iron Deficiency In Pulmonary Hypertension

• Status: Unknown status
• Trial end date: 2013-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Patients with idiopathic pulmonary arterial hypertension (IPAH) and iron deficiency were previously shown to have a decreased six-minute walking distance. Therefore the investigators hypothesized that intravenous iron administration would improve exercise capacity in iron deficient IPAH patients.

30 patients will be recruited for iron infusions. At baseline and after 12 weeks (endpoint)exercise test will be performed.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: VU University Medical Center
• Collaborator: Vifor Pharma
• Treatments: Iron

Criteria

Inclusion Criteria:

• Stable idiopathic pulmonary arterial hypertension (stable disease for at least 3 months)

• iron deficiency (serum iron below 10 μmol/l, decreased transferrin saturation (< 15% in females and < 20% in males) and serum ferritin < 100 μg/l) irrespective of the coexistence of anaemia

Exclusion Criteria:

• Current iron therapy (oral or iv)

• Current other study medication for PAH

• History of anaemia or current treatment for anaemia

• Liver function impairment

• Chronic disease other than PAH (rheumatism, asthma, chronic infection)

• Acute infection